Skip to main content
. 2020 Feb 1;10(2):473–490.

Figure 6.

Figure 6

CD8 T cell recruitment into the tumor site contributed to the synergistic efficacy. A. MC38-OVA cells were pretreated with Cis or Oxa for 24 hours, and the medium was changed to 5% FBS for incubation for another 24 hours. Migration assays were performed with culture supernatant, and the cell number of activated OT-I cells migrating to the lower chamber was determined with imaging under a microscope at a magnification of 100×. B. MC38-OVA cells were treated with increasing doses of Cis or Oxa for 24 hours, and chemokine mRNA expression was determined by qRT-PCR and calculated as using the formula 2-∆∆CT, with the GAPDH gene used as an endogenous control. Error bars, SEM. C. Treatment schedule of MC38 tumor-bearing mice comparing FTY720 blockade and vehicle control. MC38 cells were inoculated into C57BL/6 mice (n = 5) on day 0, and then intraperitoneally treated with Oxa (day 6) and/or anti-PD-1 (days 9, 13 and 17). FTY720 (20 μg/mouse) or vehicle control was intraperitoneally administered from day 6 to day 15. D. Tumor growth curve (left panel), survival curve (middle panel) and the percentage of tumor-free mice (right panel) were monitored and analyzed. *, P < 0.05; **, P < 0.01; ****, P < 0.0001 the combination group (Oxa plus anti-PD-1 antibodies) compared with the untreated group (Con); #, P < 0.05; ####, P < 0.0001; the combination group (Oxa plus anti-PD-1 antibodies) compared with the group treated with the combination of drugs (Oxa plus anti-PD-1 antibodies) and FTY720.